IDEMIA Provides Avinor Oslo Airport with Its Latest Facial Recognition Technology
Oslo Airport has improved its passenger experience through the deployment of MorphoFace, IDEMIA’s facial capture solution for its new Automated Border Control gates, driven by IDEMIA’s MorphoWAY solution.
Following the successful launch of the product at Changi Terminal 4 and integration into the Customs Gates in New Zealand, this is IDEMIA’s MorphoFace first deployment in Europe. The new system, launched in time before the summer peak, replaces an older infrastructure with the latest technology on the market and expands automated border control to Departures at Oslo Airport.
IDEMIA’s technology captures the face on the move, using no moving parts or additional lighting. Thanks to its small form factor, MorphoFace provides an unobstructed view over all gates, enhancing both passenger experience and overall security.
The tailor-made project was executed in close cooperation with Avinor, Norway Police and local partner Seca Solutions AS, part of Dormakaba Group.
IDEMIA’s Border Control solutions are configurable to fit specific local environments and requirements. In addition to an arrival and departure process, this deployment provides a remote monitoring solution for the Norwegian Police - with Avinor as the official contract partner - to handle alerts during a passenger crossing and interfaces to systems (national, European and International) to support the immigration and emigration border processes.
IDEMIA’s complete range of products for traveler processing addresses authentication of passengers prior to arrival to passenger facilitation and tracking in the airport, supporting governments, airports and airlines to address the latest challenges of today.
“Many existing Automated Border Control infrastructures in Europe are now almost 10 years old and need a new and fresh approach. Our solution allows Oslo Airport to reinvent its passenger experience. We thank Oslo Airport for choosing IDEMIA for this improvement and look forward to further developing and inspiring future innovations”, explains Philippe BARREAU, Executive Vice-President of Citizen Identity and Public Security activities at IDEMIA.
OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with
the ambition to provide a secure environment enabling citizens and
consumers alike to perform their daily critical activities (such as pay,
connect, travel and vote), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable transactions for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
OT (Oberthur Technologies) and Safran Identity & Security (Morpho) have joined forces to form IDEMIA. With close to $3 billion in revenues and 14,000 employees around the world, IDEMIA serves clients in 180 countries.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Luxury Pre-War Elevator Building in Prestigious Brooklyn Heights Offered for Sale19.6.2019 16:12:00 CEST | Pressemelding
Holliday Fenoglio Fowler, L.P. (HFF) announces it has been selected to exclusively market the sale of 25 Monroe Place, a 12-story, 67-unit, luxury apartment building located in the Brooklyn Heights neighborhood of Brooklyn, New York. This offering provides a rare opportunity to acquire a trophy asset in the most sought-after neighborhood in Brooklyn. The vast majority of the property is comprised of fair-market units not subject to rent stabilization. 25 Monroe Place is situated in the Brooklyn Heights historic district, which provides immediate access to Manhattan, the Brooklyn Waterfront, Brooklyn Bridge Park, Downtown Brooklyn and DUMBO. Brooklyn Heights is characterized by charming brownstones and plush tree-lined streets, and the property is surrounded by medium- and low-density buildings that provide water and Manhattan skyline views. Built in 1938, 25 Monroe Place combines pre-war architectural elements and spacious apartment layouts with newly upgraded condo-quality finishes, i
Shopify Unveils New Innovations to Transform Commerce for Merchants and Consumers Globally19.6.2019 15:30:00 CEST | Pressemelding
Today, Shopify Inc. (NYSE:SHOP) (TSX:SHOP), the leading multi-channel commerce platform, unveiled the latest in commerce technology at Shopify Unite, the annual conference that brings together the company’s global partner and developer community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005550/en/ Shopify Fulfillment Network (Graphic: Business Wire) “Shopify’s real power comes from the variety and strength of our ecosystem,” said Shopify CEO Tobi Lutke. "Unite gives our developer and partner community access to our product roadmap. Together, and only together, we can shape the future of commerce and empower entrepreneurs around the world.” This year, Shopify is transforming commerce by announcing platform enhancements and updates focused on giving direct-to-consumer brands everything they need to build and manage a business. Shopify’s innovations include a newly updated Shopify Plus platform for enterprise brands
Geri Horner Test Drives RockStar Suites aboard Virgin Voyages’ Scarlet Lady19.6.2019 14:01:00 CEST | Pressemelding
Virgin Voyages is upping the game for its top suites aboard the highly anticipated Scarlet Lady, with new offerings to ensure that Mega RockStars won’t have to worry about a thing during their voyage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005107/en/ Geri Horner of the Spice Girls testing out Virgin Voyages Mega Rockstar Suites in New Video (Photo: Business Wire) Geri Horner Test Drives RockStar Suites In celebration of the expanded offerings, the brand has today released exclusive video content of the suites, which features Virgin Group founder, Sir Richard Branson, and legendary British pop star, Geri Horner, of the hugely successful girl group, the Spice Girls. The video documents Horner test driving the Virgin Voyages ‘Gorgeous Suite,’ one of the ship’s most glamorous cabins, as a favor to her longtime friend, Branson. Following Horner’s journey through the suite, the footage chronicles her full RockStar ex
Survey of SAP Licensees Reveals Two-Thirds Have No Plans or Are Undecided About Migrating to New S/4HANA Product19.6.2019 13:00:00 CEST | Pressemelding
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today revealed the findings from its recent survey of SAP licensees conducted to better understand their plans for S/4HANA and the impact of SAP’s planned 2025 end of mainstream maintenance support for Business Suite 7 core applications on their IT roadmap plans. Of the IT leaders surveyed who are currently running SAP’s Business Suite 7 or older releases, two-thirds state they either have no plans to migrate to S/4HANA (35%) or are undecided about moving to S/4HANA (32%). The top reasons cited include “lack of resources,” “no business justification,” and a preference to “maximize investment in current applications.” The number of respondents who stated they have no plans to migrate or are undecided has risen slightly from a previous survey in 2017 – at that time 65% of IT leaders stat
Moody’s Analytics Wins Six Risk Technology Awards19.6.2019 12:45:00 CEST | Pressemelding
Moody’s Analytics, a global provider of financial intelligence, has won six categories in the 2019 Risk Technology Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005226/en/ Bank ALM System of the Year Credit Data Provider of the Year Wholesale Credit Modelling Software of the Year Enterprise-Wide Stress Testing Product of the Year IFRS 9 – ECL Modelling Solution of the Year IFRS 9 – Enterprise Solution of the Year “This recognition from Risk is highly gratifying,” said Mark Almeida, President of Moody’s Analytics. “Our clients face many different challenges, which Moody’s Analytics can solve with our unique combination of data, models, software, and services. These awards showcase our extensive capabilities and success in solving our clients’ problems.” “We applaud Moody’s Analytics for its strong showing in this year’s Risk Technology Awards,” said Antony Chambers, Publisher of Risk. “Taking the top spot in si
Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases19.6.2019 12:30:00 CEST | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190619005092/en/ Dysregulated and/or mutated proteins play a central role in the development and progression of many human diseases. Nurix’s technology platform is focused on the manipulation of the ubiquitin system and its component E3 ligases, the key enzymes responsible for controlling protein levels in human cells. Under the multi-year collaboration, Nurix will utilize its proprietary drug discovery platform to identify novel agents that utilize E3 ligases to induce degradation of specified drug targets and Gilead